Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 30Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 15Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Sarcoma 13Ovarian Neoplasms 12Breast Neoplasms 12Triple Negative Breast Neoplasms 9Nasopharyngeal Carcinoma 9Esophageal Squamous Cell Carcinoma 9Cholangiocarcinoma 9Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Osteosarcoma 6Lung Neoplasms 6Pancreatic Neoplasms 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Neoplasms 4Melanoma 4Solid Tumor 3Recurrence 3Neoplasm Metastasis 3Liver Neoplasms 3Glioma 3Gastric Adenocarcinoma 3Carcinoma, Adenoid Cystic 3

Interventions

durvalumab 3Carboplatin 2sotorasib 1sintilimab 1necitumumab 1ceralasertib 1camrelizumab 1apatinib 1alectinib 1Radiotherapy 1Radiosurgery 1Gemcitabine 1Etoposide 1Erlotinib Hydrochloride 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Respiratory Tract Diseases × apatinib × Clear all
NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
144 enrolled
Thoracic

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡